Candesartan use in hypertrophic and non-obstructive cardiomyopathy estate (The CHANCE): a double-blind, placebo-controlled, randomized, multicenter study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2007
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms CHANCE
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2007 Results have been reported.
- 27 Feb 2007 New trial record.